

**Decnupaz™**  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

# YOUR GUIDE TO BPDCN AND DECNUPAZ

THE MISSION IN BPDCN:

**REMISSION,  
RIGHT WHERE  
YOU BELONG**

In a clinical trial that, in part, included 33 people who received DECNUPAZ as their first treatment for BPDCN with no central nervous system involvement:

- 70% achieved complete remission. Of the people who achieved complete remission, half were estimated to still respond to DECNUPAZ for at least 9.7 months

Remission or complete remission means that all signs of cancer have disappeared in response to treatment, but there may be some skin abnormalities that remain.

**DECNUPAZ:** The first and only FDA-approved treatment for BPDCN that's **given outpatient from the start**, once every 21 days. No hospital stay for infusions can mean more time to focus on what matters during treatment. Actual clinical time may vary, including premedication and post-infusion monitoring

## USE

### What is DECNUPAZ?

DECNUPAZ is a prescription medicine used to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

It is not known if DECNUPAZ is safe and effective in children.

## IMPORTANT SAFETY INFORMATION

### What is the most important information I should know about DECNUPAZ?

DECNUPAZ can cause serious side effects, including:

- **Liver problems (hepatotoxicity), including veno-occlusive disease (blockage of the small veins in the liver) that can be severe, life-threatening, or may lead to death.** Your healthcare provider will do blood tests before each dose of DECNUPAZ and during treatment with DECNUPAZ to check for liver problems. Tell your healthcare provider right away if you develop signs or symptoms of liver problems, including:
  - yellowing of the skin or eyes
  - fast weight gain
  - dark urine
  - pain in your stomach (abdomen)
  - swelling of your stomach

Continue reading information about Liver Problems on page 4.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17.

Please see full Prescribing Information, including Medication Guide.



## Learn what's next

Facing BPDCN, or blastic plasmacytoid dendritic cell neoplasm, can feel overwhelming, but knowing more about how it is diagnosed and what treatment may involve can help ease some of the uncertainty. **The more you learn about what happens next, the more prepared you can feel while navigating this experience.** This brochure is for you to learn more about how DECNUPAZ may help you so that you can move forward in your treatment.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17.  
Please see full [Prescribing Information](#), including [Medication Guide](#).



**Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg



## What's inside

Understanding BPDCN .....	4
About DECNUPAZ .....	6
Receiving treatment.....	7
Results with DECNUPAZ.....	8
Side effects.....	10
Resources & support.....	12
Important Safety Information .....	16

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17.  
Please see full Prescribing Information, including Medication Guide.

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

## What is BPDCN?

BPDCN, or blastic plasmacytoid dendritic cell neoplasm, is a rare and rapidly progressing blood cancer.

### How BPDCN can affect you

BPDCN can affect many different parts of your body, including:



Skin



The central nervous system, which includes the brain and spinal cord



Blood



Lymph nodes



Soft tissue inside bones, or bone marrow



Spleen

BPDCN can affect many different parts of the body, and it's important to remember **your symptoms may look different from other people with a BPDCN diagnosis**. Like many people who have been diagnosed with BPDCN, you may have experienced skin lesions, such as rashes, bruise-like spots, or raised bumps. Other symptoms you may have experienced could include tiredness, swollen lymph nodes, or discomfort in the stomach area.

### IMPORTANT SAFETY INFORMATION (Cont'd)

#### What is the most important information I should know about DECNUPAZ? (Cont'd)

Your healthcare provider will check you for liver problems during your treatment with DECNUPAZ and may provide treatment for your side effects. Your healthcare provider may also delay or stop treatment with DECNUPAZ if you have severe liver problems.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

## UNDERSTANDING BPDCN (Cont'd)



### Your BPDCN diagnosis

Your healthcare provider will perform a biopsy to look for CD123. A **biopsy** is when cells or tissue is removed to look for abnormalities that can help doctors diagnose BPDCN. This can be a bone marrow biopsy and, if you have skin lesions, may also include a skin biopsy.

**CD123 is a protein normally found on healthy blood cells, but it is found in high amounts on the cancerous blood cells in people with BPDCN. Detecting CD123 is one factor that can help doctors diagnose BPDCN.**



#### Looking for more information about BPDCN?

Advocacy and support organizations have helpful educational materials that you can access to learn more about BPDCN.

**Check out pages 14–15, or click [here](#) to learn more.**

### Your BPDCN treatment: DECNUPAZ

A healthcare provider has recommended a targeted therapy, like DECNUPAZ. Targeted therapies are not chemotherapy. Instead, they target specific receptors or proteins on cells; for example, **CD123** is a therapeutic target in BPDCN.

**Even though BPDCN is very rare, there are treatments available. DECNUPAZ was approved specifically for adult patients with BPDCN. It may help patients like you.**

### IMPORTANT SAFETY INFORMATION (Cont'd)

#### What should I tell my healthcare provider before receiving DECNUPAZ?

**Tell your healthcare provider about all of your medical conditions, including if you:**

- have liver problems
- are allergic to sulfites
- have asthma
- have kidney problems
- are pregnant or plan to become pregnant. DECNUPAZ can harm your unborn baby.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

## What is DECNUPAZ?

DECNUPAZ may affect cancer cells as well as certain healthy cells in the body, which can cause side effects.

**DECNUPAZ is a type of medicine called an antibody-drug conjugate (ADC). ADCs are designed to attack cancer in a targeted way, which is different from traditional chemotherapies.**

DECNUPAZ works by targeting BPDCN cells that have a protein on them called **CD123**. CD123 is found on BPDCN cells and on other nearby cells.

## How DECNUPAZ works in your body



## IMPORTANT SAFETY INFORMATION (Cont'd)

### What should I tell my healthcare provider before receiving DECNUPAZ? (Cont'd)

#### Females who are able to become pregnant:

- Your healthcare provider will check for pregnancy before you start treatment with DECNUPAZ.
- Use effective birth control (contraception) during treatment with DECNUPAZ and for 7 months after your last dose.
- Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with DECNUPAZ.




Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

## What can I expect during treatment with DECNUPAZ?

DECNUPAZ can be given as a **short outpatient infusion**. As an outpatient infusion, this means that you will most likely not need to be admitted to or spend the night at a healthcare facility to receive treatment. **See below for what your experience may look like, including premedication and monitoring expectations, and talk to your healthcare provider about what you can expect before and after treatment.**

### Your treatment plan

 <p><b>Given as an IV infusion</b> Directly into the vein.</p> <p>IV=intravenous</p>	 <p><b>Infusion takes ~15–30 minutes</b></p> <p>Your healthcare provider will tell you how long your total treatment may take.</p> <p>Your total treatment time will be longer than your infusion. Before each infusion, you will receive premedications. After each infusion, you will need to be monitored.</p>	 <p><b>Given once every 21 days</b></p> <p>A healthcare provider will decide how many infusions of DECNUPAZ you may receive. Talk to your healthcare provider about what your full treatment plan is and how long you may be on treatment.</p>
---	--	---

### What to expect with treatment

- **The day before each DECNUPAZ infusion**
  - You will receive a medicine, known as a premedication, to help prepare your body for the infusion and try to prevent any infusion-related reactions that may occur
    - Some premedications will be given orally and some will be given as an IV infusion
- **On the day of each DECNUPAZ infusion**
  - You will receive **premedications 30–60 minutes before each DECNUPAZ infusion**, so you will have to arrive early
  - **After each DECNUPAZ infusion**, your healthcare provider will need to monitor you
    - You will be monitored for **at least 4 hours** after the first infusion
    - After each future infusion, you will be monitored for **at least 1 hour**

### Pay attention to how you feel during and after your infusions

During treatment, it's important that you pay close attention to how you feel and share any changes with your healthcare team. Your healthcare team will also check for side effects and may provide treatment to help ease them. If side effects become severe, your treatment may be adjusted, delayed, or stopped.

**Talk to your healthcare team about anything you may be experiencing during your treatment.**

### IMPORTANT SAFETY INFORMATION (Cont'd)

#### What should I tell my healthcare provider before receiving DECNUPAZ? (Cont'd)

##### Males who have female partners who are able to become pregnant:

- Use an effective birth control during treatment with DECNUPAZ and for 4 months after your last dose of DECNUPAZ.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17.

Please see full Prescribing Information, including Medication Guide.



**Decnupaz™**  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

# How can DECNUPAZ help me reach my treatment goals?

The goal of treating BPDCN with DECNUPAZ is to achieve remission. **Remission** or **complete remission** means that all signs of cancer have disappeared in response to treatment, but there may be some skin abnormalities that remain.

## DECNUPAZ helped many people with BPDCN achieve remission

### About the clinical trial

In the clinical trial, DECNUPAZ was given to 84 people living with BPDCN:

- 33** people received DECNUPAZ as a first treatment\*
  - 22 were newly diagnosed with BPDCN as their first and only blood cancer
  - 11 were newly diagnosed with BPDCN but also have another or previously had another blood cancer

**51** people either relapsed after a previous treatment or did not respond to previous treatment such as chemotherapy or another targeted therapy†

\*With no central nervous system involvement.

†Can include people with BPDCN with central nervous system involvement that was previously treated.

## If you are receiving DECNUPAZ as a first treatment, remission may be possible

In the clinical trial, the majority of people reached remission when DECNUPAZ was used as their first treatment

In all people who received DECNUPAZ as their first treatment for BPDCN



achieved complete remission

Of the people who achieved complete remission, half were estimated to still remain in remission for at least 9.7 months

**49%** (16 out of 33 people) achieved complete remission with no skin abnormalities remaining

**21%** (7 out of 33 people) achieved complete remission with some skin abnormalities remaining



people went on to receive a **stem cell transplant** after DECNUPAZ treatment

## IMPORTANT SAFETY INFORMATION (Cont'd)

### What should I tell my healthcare provider before receiving DECNUPAZ? (Cont'd)

- are breastfeeding or plan to breastfeed. It is not known if DECNUPAZ passes into your breast milk. Do not breastfeed during treatment with DECNUPAZ and for 1 month after the last dose.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect DECNUPAZ and increase your risk of side effects.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17.

Please see full Prescribing Information, including Medication Guide.

**Decnupaz™**  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

## RESULTS WITH DECNUPAZ (Cont'd)



Even if your BPDCN came back or did not respond to previous treatment, remission may be possible with DECNUPAZ

In the clinical trial, DECNUPAZ helped some people with BPDCN who relapsed after a previous treatment or did not respond to previous treatment achieve remission

In all people with previously treated BPDCN

**16%**

(8 out of 51 people)

achieved complete remission

Of the people who achieved complete remission, half were estimated to still remain in remission for at least 9.2 months

**14%** (7 out of 51 people) achieved complete remission with no skin abnormalities remaining

**2%** (1 out of 51 people) achieved complete remission with some skin abnormalities remaining

**12%**

(6 out of 51 people)

went on to receive a **stem cell transplant** after DECNUPAZ treatment

### IMPORTANT SAFETY INFORMATION (Cont'd)

What are the possible side effects of DECNUPAZ?

DECNUPAZ can cause serious side effects, including:

- **Liver problems (hepatotoxicity), including veno-occlusive disease (blockage of the small veins in the liver) that can be severe, life-threatening, or may lead to death.** Your healthcare provider will do blood tests before each dose of DECNUPAZ and during treatment with DECNUPAZ to check for liver problems. Tell your healthcare provider right away if you develop signs or symptoms of liver problems, including yellowing of the skin or eyes, fast weight gain, dark urine, pain in your stomach (abdomen), or swelling of your stomach.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

# What should I know about side effects?



During treatment with DECNUPAZ, side effects may occur

## Pay attention to how you feel

It is important to pay attention to how you feel and talk to your healthcare team right away about any discomfort or change in the way you are feeling, especially if you are having symptoms.

Signs or symptoms of serious side effects to look out for:

<p><b>Liver problems</b></p> <ul style="list-style-type: none"> <li>• Yellowing of the skin or eyes</li> <li>• Pain in your stomach (abdomen)</li> <li>• Fast weight gain</li> <li>• Swelling of your stomach</li> <li>• Dark urine</li> </ul>	<p><b>Infusion-related reactions</b></p> <ul style="list-style-type: none"> <li>• Shortness of breath</li> <li>• Nausea</li> <li>• Flushing</li> <li>• Chest pain</li> <li>• Fever</li> <li>• Feeling faint or lightheaded</li> <li>• Chills</li> <li>• Vomiting</li> </ul> <p><b>Your healthcare provider should give you premedications before your infusion of DECNUPAZ to decrease your chance of having an infusion-related reaction.</b></p>	<p><b>Fluid retention</b></p> <ul style="list-style-type: none"> <li>• Swelling of your ankles or legs</li> <li>• Shortness of breath or difficulty breathing</li> <li>• Unusual weight gain</li> </ul> <p><b>Your body may hold too much fluid during treatment with DECNUPAZ.</b></p>	<p><b>Sulfite allergic reactions</b></p> <ul style="list-style-type: none"> <li>• Hives</li> <li>• Itching</li> <li>• Rash</li> <li>• Swelling of the eyes, tongue, lips</li> <li>• Chest pain</li> <li>• Trouble breathing or swallowing</li> </ul>
--	--	---	--

**Getting medical treatment right away is important.** Your healthcare provider will check you for these problems during your treatment with DECNUPAZ and may provide treatment for your side effects. Your healthcare provider may also need to change your dose, delay, or completely stop treatment with DECNUPAZ if you have severe side effects.

## IMPORTANT SAFETY INFORMATION (Cont'd)

### What are the possible side effects of DECNUPAZ? (Cont'd)

• **Infusion-related reactions (IRR).** DECNUPAZ can cause serious, life-threatening infusion-related reactions. Your healthcare provider will give you medicines the day before and on the day of your infusion of DECNUPAZ to help reduce infusion-related reactions. Your healthcare provider will check you for symptoms of infusion-related reactions during your infusion and for at least 4 hours, or longer if needed, after your first infusion, and for at least 1 hour after each of your next infusions. Tell your healthcare provider right away if you develop signs or symptoms of infusion-related reactions, including:

- shortness of breath
- nausea
- flushing
- chest pain
- fever
- feeling faint or lightheaded
- chills
- vomiting

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17.

Please see full Prescribing Information, including Medication Guide.



## SIDE EFFECTS (Cont'd)

### Most common side effects include:

- Fluid retention (edema)
- Bleeding
- Feeling tired
- Infusion-related reactions
- Muscle, bone, and joint pain
- Nausea
- Diarrhea

### Most common severe abnormal laboratory test results with DECNUPAZ include:

- Decreased white blood cell counts
- Decreased red blood cell counts
- Decreased platelet counts
- Increased blood sugar level

**These are not all of the possible side effects of DECNUPAZ.** Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

### Keep track of your symptoms

*Use the space below to take note of any side effects you may feel so you can discuss with your healthcare team. Try to include dates, severity, and symptom description in as much detail as possible.*

#### Notes:

---

---

---

---

---

---

---

---

### IMPORTANT SAFETY INFORMATION (Cont'd)

#### What are the possible side effects of DECNUPAZ? (Cont'd)

- **Fluid retention (edema).** DECNUPAZ can cause your body to hold too much fluid during treatment. Your healthcare provider may prescribe water pills (diuretic) if you develop edema. Tell your healthcare provider if you develop new or worsening edema, including:
  - swelling of your ankles or legs
  - shortness of breath or difficulty breathing
  - unusual weight gain

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg



## Are there resources available to support accessing my prescribed treatment?

During treatment with DECNUPAZ, you are not alone. We are here to help support access to your prescribed treatment. There are additional resources available to help you as well.

### IMPORTANT SAFETY INFORMATION (Cont'd)

#### What are the possible side effects of DECNUPAZ? (Cont'd)

- **Sulfite allergic reactions.** DECNUPAZ contains sodium metabisulfite, a sulfite that may cause severe, life-threatening allergic reactions in some people. Sulfite allergic reactions are more common in people with asthma than in people without asthma. Get medical help right away if you develop hives; itching; rash; swelling of the eyes, tongue, or lips; chest pain; or trouble breathing or swallowing.

#### The most common side effects include:

- fluid retention (edema)
- feeling tired
- muscle, bone, and joint pain
- bleeding
- infusion-related reactions
- nausea
- diarrhea

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

## RESOURCES & SUPPORT (Cont'd)

### DECNUPAZ Support Services is here to help you and your provider access your prescribed treatment

Talk to your healthcare provider about enrolling in DECNUAZ Support Services.

#### About DECNUAZ Support Services

Your healthcare provider can enroll you in DECNUAZ Support Services by filling out a simple form.



#### Navigating the insurance process

Once you are enrolled in DECNUAZ Support Services, we will work directly with your healthcare provider to understand your insurance coverage and explore financial assistance options.



#### Co-pay assistance

Eligible, commercially insured patients could **pay as little as \$0** for DECNUAZ.\*

#### myAbbVie Assist

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit [AbbVie.com/PatientAccessSupport](https://www.abbvie.com/PatientAccessSupport) to learn more.

\*Eligibility: Available to patients with commercial insurance coverage for DECNUAZ (pivekimab sunirine-pvzy) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit <https://decnupaz.com/copayterms> or call 1-833-746-7892 for additional information. To learn about AbbVie's privacy practices and your privacy choices, visit <https://abbvie.com/privacy>.



#### Tools to help you get started

Your doctor may provide a Patient Starter Kit with helpful information and tools to support your prescribed treatment, manage appointments, and prepare for conversations with your care team.

### IMPORTANT SAFETY INFORMATION (Cont'd)

#### What are the possible side effects of DECNUAZ? (Cont'd)

The most common severe abnormal laboratory test results with DECNUAZ include:

- decreased white blood cell counts
- decreased red blood cell counts
- decreased platelet counts
- increased blood sugar level

Your healthcare provider may decrease your dose, delay your infusion, or permanently stop treatment with DECNUAZ if you have side effects.

Please see full Important Safety Information, including BOXED WARNING, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).

**Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

# Advocacy and support organizations

Even with a rare blood cancer like BPDCN, you are not alone in your diagnosis. There are organizations that can support you throughout treatment by providing helpful information and connecting you with others.



**HealthTree Foundation** is a nonprofit organization dedicated to improving the lives of people with blood cancers and their families through education, personalized support, and community connection. They also have dedicated programs for BPDCN. HealthTree helps individuals navigate their care, supports collaboration between patients and researchers, and works to accelerate the development of more effective treatments and cures.

To access HealthTree resources, visit [HealthTree.org](https://www.healthtree.org)



The **American Cancer Society** is improving the lives of people with cancer by providing trusted education, one-on-one support, and practical assistance. Through programs such as transportation to treatment, lodging support, financial and insurance guidance, and reliable cancer information, the organization helps patients and their families navigate care and reduce barriers during every stage of the cancer journey.

To access American Cancer Society resources, visit [cancer.org](https://www.cancer.org)

Information is provided by AbbVie Inc. and intended for informational purposes only. It is not meant to replace your healthcare provider's medical advice or treatment. The organizations listed above have not endorsed AbbVie Inc. or any of its respective products or services. AbbVie Inc. has listed these organizations only as a convenience and according to the permissions granted by their respective terms of use. Each organization has its own terms and conditions and privacy policy that you should read if you choose to contact any of them.

## IMPORTANT SAFETY INFORMATION (Cont'd)

### What are the possible side effects of DECNUPAZ? (Cont'd)

DECNUPAZ may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of DECNUPAZ. Call your doctor for medical advice about side effects.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).



**Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

## RESOURCES & SUPPORT (Cont'd)




### **Blood Cancer United**

**Blood Cancer United** supports people living with blood cancers, including rare cancers such as BPDCN, and their families through educational resources, patient and caregiver support, and advocacy efforts focused on access to care. By funding research, raising awareness, and connecting individuals to a global community of advocates, Blood Cancer United helps patients better understand their diagnosis, find support, and navigate the emotional and financial challenges of living with a blood cancer.

To access **Blood Cancer United** resources, visit [bloodcancerunited.org](https://www.bloodcancerunited.org)

Information is provided by AbbVie Inc. and intended for informational purposes only. It is not meant to replace your healthcare provider's medical advice or treatment. The organizations listed above have not endorsed AbbVie Inc. or any of its respective products or services. AbbVie Inc. has listed these organizations only as a convenience and according to the permissions granted by their respective terms of use. Each organization has its own terms and conditions and privacy policy that you should read if you choose to contact any of them.

To view more information on DECNUPAZ Support Services, access advocacy and support organizations, or download resources, visit [DECNUPAZ.com/support-and-resources](https://www.decnpaz.com/support-and-resources)



### **IMPORTANT SAFETY INFORMATION (Cont'd)**

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](https://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Please see full Prescribing Information, including BOXED WARNING, or visit [https://www.rxabbvie.com/pdf/decnupaz\\_pi.pdf](https://www.rxabbvie.com/pdf/decnupaz_pi.pdf).

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit [AbbVie.com/PatientAccessSupport](https://www.abbvie.com/PatientAccessSupport) to learn more.

Please see full Important Safety Information, including BOXED WARNING, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

# IMPORTANT SAFETY INFORMATION

## USE

### What is DECNUPAZ?

DECNUPAZ is a prescription medicine used to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

It is not known if DECNUPAZ is safe and effective in children.

## IMPORTANT SAFETY INFORMATION

### What is the most important information I should know about DECNUPAZ?

DECNUPAZ can cause serious side effects, including:

- **Liver problems (hepatotoxicity), including veno-occlusive disease (blockage of the small veins in the liver) that can be severe, life-threatening, or may lead to death.** Your healthcare provider will do blood tests before each dose of DECNUPAZ and during treatment with DECNUPAZ to check for liver problems. Tell your healthcare provider right away if you develop signs or symptoms of liver problems, including:
  - yellowing of the skin or eyes
  - pain in your stomach (abdomen)
  - fast weight gain
  - swelling of your stomach
  - dark urine

Your healthcare provider will check you for liver problems during your treatment with DECNUPAZ and may provide treatment for your side effects. Your healthcare provider may also delay or stop treatment with DECNUPAZ if you have severe liver problems.

### What should I tell my healthcare provider before receiving DECNUPAZ?

Tell your healthcare provider about all of your medical conditions, including if you:

- have liver problems
- are allergic to sulfites
- have asthma
- have kidney problems
- are pregnant or plan to become pregnant. DECNUPAZ can harm your unborn baby.

#### Females who are able to become pregnant:

- Your healthcare provider will check for pregnancy before you start treatment with DECNUPAZ.
- Use effective birth control (contraception) during treatment with DECNUPAZ and for 7 months after your last dose.
- Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with DECNUPAZ.

#### Males who have female partners who are able to become pregnant:

- Use an effective birth control during treatment with DECNUPAZ and for 4 months after your last dose of DECNUPAZ.
- are breastfeeding or plan to breastfeed. It is not known if DECNUPAZ passes into your breast milk. Do not breastfeed during treatment with DECNUPAZ and for 1 month after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect DECNUPAZ and increase your risk of side effects.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17. Please see full [Prescribing Information](#), including [Medication Guide](#).

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

## IMPORTANT SAFETY INFORMATION (Cont'd)

### What are the possible side effects of DECNUPAZ?

DECNUPAZ can cause serious side effects, including:

- **Liver problems (hepatotoxicity), including veno-occlusive disease (blockage of the small veins in the liver) that can be severe, life-threatening, or may lead to death.** Your healthcare provider will do blood tests before each dose of DECNUPAZ and during treatment with DECNUPAZ to check for liver problems. Tell your healthcare provider right away if you develop signs or symptoms of liver problems, including yellowing of the skin or eyes, fast weight gain, dark urine, pain in your stomach (abdomen), or swelling of your stomach.
- **Infusion-related reactions (IRR).** DECNUPAZ can cause serious, life-threatening infusion-related reactions. Your healthcare provider will give you medicines the day before and on the day of your infusion of DECNUPAZ to help reduce infusion-related reactions. Your healthcare provider will check you for symptoms of infusion-related reactions during your infusion and for at least 4 hours, or longer if needed, after your first infusion, and for at least 1 hour after each of your next infusions. Tell your healthcare provider right away if you develop signs or symptoms of infusion-related reactions, including:
  - shortness of breath
  - flushing
  - fever
  - chills
  - nausea
  - chest pain
  - feeling faint or lightheaded
  - vomiting
- **Fluid retention (edema).** DECNUPAZ can cause your body to hold too much fluid during treatment. Your healthcare provider may prescribe water pills (diuretic) if you develop edema. Tell your healthcare provider if you develop new or worsening edema, including:
  - swelling of your ankles or legs
  - shortness of breath or difficulty breathing
  - unusual weight gain
- **Sulfite allergic reactions.** DECNUPAZ contains sodium metabisulfite, a sulfite that may cause severe, life-threatening allergic reactions in some people. Sulfite allergic reactions are more common in people with asthma than in people without asthma. Get medical help right away if you develop hives; itching; rash; swelling of the eyes, tongue, or lips; chest pain; or trouble breathing or swallowing.

The most common side effects include:

- fluid retention (edema)
- feeling tired
- muscle, bone, and joint pain
- bleeding
- infusion-related reactions
- nausea
- diarrhea

The most common severe abnormal laboratory test results with DECNUPAZ include:

- decreased white blood cell counts
- decreased red blood cell counts
- decreased platelet counts
- increased blood sugar level

Your healthcare provider may decrease your dose, delay your infusion, or permanently stop treatment with DECNUPAZ if you have side effects.

DECNUPAZ may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of DECNUPAZ. Call your doctor for medical advice about side effects.

**You are encouraged to report negative side effects of prescription drugs to the FDA.**

Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Please see full Prescribing Information, including **BOXED WARNING**, or visit [https://www.rxabbvie.com/pdf/decnupaz\\_pi.pdf](https://www.rxabbvie.com/pdf/decnupaz_pi.pdf).

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit [AbbVie.com/PatientAccessSupport](http://AbbVie.com/PatientAccessSupport) to learn more.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17. Please see full Prescribing Information, including Medication Guide.

 **Decnupaz**<sup>™</sup>  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg





 **Decnupaz™**  
pivekimab sunirine-pvzy  
injection for intravenous use 2 mg

THE MISSION IN **BPDCN**:

**REMISSION,  
RIGHT WHERE  
YOU BELONG**



In a clinical trial that featured 33 people who received DECNUPAZ as their first treatment for BPDCN, 70% achieved complete remission. Of the people who achieved complete remission, half were estimated to still remain in remission for at least 9.7 months.

Remission or complete remission means that all signs of cancer have disappeared in response to treatment, but there may be some skin abnormalities that remain.



Take the next step toward treatment with DECNUPAZ.  
Visit [DECNUPAZ.com](https://www.decnupez.com) to learn more.

## USE

### What is DECNUPAZ?

DECNUPAZ is a prescription medicine used to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

It is not known if DECNUPAZ is safe and effective in children.

## SELECT IMPORTANT SAFETY INFORMATION

**DECNUPAZ can cause serious side effects, including:**

- **Liver problems (hepatotoxicity), including veno-occlusive disease (blockage of the small veins in the liver) that can be severe, life-threatening, or may lead to death.**
- **Infusion-related reactions (IRR).** DECNUPAZ can cause serious, life-threatening infusion-related reactions.
- **Fluid retention (edema).** DECNUPAZ can cause your body to hold too much fluid during treatment.
- **Sulfite allergic reactions.** DECNUPAZ contains sodium metabisulfite, a sulfite that may cause severe, life-threatening allergic reactions in some people.

**The most common side effects of DECNUPAZ include:** fluid retention; bleeding; feeling tired; infusion-related reactions; muscle, bone, and joint pain; nausea; and diarrhea.

**The most common severe abnormal laboratory test results with DECNUPAZ include:** decreased white blood cell counts, decreased red blood cell counts, decreased platelet counts, and increased blood sugar level.

Please see full Important Safety Information, including **BOXED WARNING**, throughout this brochure and on pages 16-17.

Please see full [Prescribing Information](#), including [Medication Guide](#).

**abbvie**

© 2026 AbbVie. All rights reserved.  
DECNUPAZ and its design are trademarks of ImmunoGen, Inc., an AbbVie company.  
US-PVEK-250045 June 2026